SHBG (Extended) Lab Test: Which Drugs Distort Your Results

What "SHBG (Extended)" Actually Means

The "extended" designation tells you this is not a standalone SHBG number. It is a panel that reports total SHBG concentration (measured directly by immunoassay) alongside calculated free testosterone and, at some reference laboratories, calculated free estradiol. The calculation uses the law-of-mass-action formula derived from binding constants for albumin and SHBG, not a direct measurement of free hormone in solution.

Why does that distinction matter? Because SHBG is the dominant binding protein for both testosterone and estradiol in women. Roughly 66 to 78 percent of circulating testosterone is SHBG-bound and therefore biologically inactive. A drug that doubles your SHBG can cut your free testosterone in half without touching your total testosterone at all. The total testosterone number on your basic panel will look identical. The extended panel catches that shift.

How SHBG Is Measured

Most clinical laboratories use a two-site sandwich immunoassay or electrochemiluminescence immunoassay (ECLIA). The Endocrine Society recommends liquid chromatography-tandem mass spectrometry (LC-MS/MS) as the gold standard for total testosterone in women, partly because direct immunoassays struggle at low female concentrations. SHBG itself is measured by immunoassay with generally acceptable precision, but free testosterone calculated from a low-quality total testosterone input still carries substantial error.

Reference Ranges by Life Stage

Reference ranges shift considerably across a woman's life, and most laboratory printouts give you only one adult female range.

| Life stage | Approximate SHBG range (nmol/L) | |---|---| | Reproductive age (non-pregnant) | 18-144 | | Follicular phase | 40-120 | | Luteal phase | 35-110 | | Pregnancy (first trimester) | 150-400 | | Pregnancy (third trimester) | 400-1,000+ | | Perimenopause | 25-100 | | Post-menopause (no HRT) | 20-75 | | Post-menopause (oral estrogen) | 60-160 |

The Menopause Society notes that post-menopausal SHBG declines alongside estradiol, and that route of estrogen administration determines whether SHBG rises.

Drugs That Raise SHBG and Why That Matters

When a medication raises SHBG, more testosterone and estradiol get bound and locked away. Your calculated free testosterone falls. Symptoms of low androgen (low libido, fatigue, difficulty building muscle) may appear even though your total testosterone looks fine. This is the most common drug-SHBG interaction a woman encounters.

Oral Estrogens and Combined Hormonal Contraceptives

Oral estrogen is the single strongest clinical driver of SHBG elevation. The first-pass hepatic effect of swallowed estrogen stimulates SHBG synthesis directly in the liver. A 2013 meta-analysis in Contraception found that combined oral contraceptive pills (COCs) raise SHBG by 200 to 400 percent compared to baseline. The elevation persists for at least six months after stopping in some women, a window now sometimes called "post-pill SHBG suppression lag" in the androgen deficiency literature.

The progestin component matters. Pills containing a strongly androgenic progestin (levonorgestrel, norethindrone) attenuate the SHBG rise compared to pills containing a non-androgenic progestin (drospirenone, desogestrel, norgestimate). Apter et al. (2014, Contraception) showed SHBG was significantly higher with drospirenone-containing pills than with levonorgestrel-containing pills at 6 months.

Clinical bottom line: If you are on any oral contraceptive and your provider orders SHBG (extended), the free testosterone result reflects your pill-modified SHBG, not your true baseline. Ideally, if the clinical question is androgen excess or deficiency unrelated to contraception, testing should happen after at least 3 months off hormonal contraceptives or with a progestin-only or non-hormonal method.

Oral Thyroid Hormone (Levothyroxine) and Hyperthyroidism

Thyroid hormone stimulates hepatic SHBG production. Both exogenous hyperthyroidism from over-replacement with levothyroxine and endogenous hyperthyroidism (Graves disease) raise SHBG significantly. The effect is dose-dependent. Women treated for thyroid cancer who are deliberately kept TSH-suppressed on high-dose levothyroxine will have chronically elevated SHBG.

Hypothyroidism does the opposite. Untreated or undertreated hypothyroidism suppresses SHBG, which can make free testosterone look artificially elevated.

Anticonvulsants (Enzyme-Inducing)

Older anticonvulsants, particularly phenytoin, carbamazepine, oxcarbazepine, and phenobarbital, induce hepatic CYP enzymes and also raise SHBG independently. A study in Epilepsia documented elevated SHBG in women on carbamazepine compared to controls. For a woman already prone to low free testosterone (e.g., adrenal insufficiency, hypopituitarism), this drug class may compound symptoms.

Newer anticonvulsants such as levetiracetam, lamotrigine, and valproate have less effect on SHBG, though valproate has its own androgen-raising effect through a different mechanism (see below).

Tamoxifen and Selective Estrogen Receptor Modulators (SERMs)

Tamoxifen acts as a partial estrogen agonist in the liver, increasing SHBG production. Published data in the Journal of Clinical Endocrinology and Metabolism confirmed SHBG rises during tamoxifen therapy. For breast cancer survivors managing sexual health, the elevated SHBG compounds the direct symptom burden of low estrogen by further suppressing calculated free testosterone, a driver of libido and arousal.

Raloxifene has a similar hepatic agonist effect and likewise raises SHBG.

Drugs That Lower SHBG and Why That Matters

A medication-driven drop in SHBG raises free testosterone and free estradiol. Depending on context, this can be therapeutic (restoring libido when SHBG was pathologically elevated) or problematic (amplifying androgen excess in PCOS or producing unwanted androgenic side effects).

Androgens and Anabolic Steroids

Exogenous testosterone, DHEA supplements, danazol, and anabolic steroids all suppress hepatic SHBG synthesis. The suppression is rapid and substantial. In transgender men receiving testosterone therapy, SHBG falls by approximately 50 percent within the first three months. For cisgender women on low-dose testosterone for HSDD or post-menopausal androgen deficiency, SHBG drops in proportion to dose and route, with injectable or pellet formulations producing greater suppression than topical gel.

This suppression creates a feedback amplification: lower SHBG means more free testosterone from the same total dose, which means a dose that looked conservative on paper may be pharmacologically more potent than intended.

Progestins With High Androgenic Activity

Not all progestins behave alike. Norethindrone acetate, levonorgestrel, norgestrel, and particularly high-dose medroxyprogesterone acetate (Depo-Provera) lower SHBG through androgenic receptor activity. A comparative study in Fertility and Sterility showed SHBG was measurably lower in women on Depo-Provera than in those on non-androgenic progestin methods.

For a woman with PCOS who is already SHBG-deficient, choosing a progestin-only pill containing norethindrone instead of a drospirenone-containing COC can worsen her effective androgen load even if her total testosterone is unchanged.

Insulin and Insulin Resistance

Insulin directly inhibits hepatic SHBG synthesis. This is why SHBG is low in metabolic syndrome, type 2 diabetes, and PCOS. A landmark analysis in Diabetes Care showed that higher fasting insulin was independently associated with lower SHBG in women, even after adjusting for adiposity. The relationship is so consistent that some researchers have proposed SHBG as a biomarker of insulin sensitivity rather than simply a hormone transport protein.

High-dose exogenous insulin therapy (common in type 1 diabetes managed at high doses) also suppresses SHBG. For a woman with type 1 diabetes and already marginal ovarian androgen production, this can translate into genuinely low free testosterone on labs despite unremarkable total testosterone.

Glucocorticoids

Systemic glucocorticoids (prednisone, dexamethasone, methylprednisolone) suppress SHBG at therapeutic doses, though the effect is smaller than that of androgens. Handelsman (2017, Endocrine Reviews) summarizes glucocorticoid effects on the hypothalamic-pituitary-gonadal axis, which include both central suppression and peripheral SHBG reduction.

Women on long-term glucocorticoids for lupus, rheumatoid arthritis, asthma, or inflammatory bowel disease should have SHBG interpreted with that suppressive context in mind.

Valproate (Valproic Acid)

Valproate is unusual: it does not lower SHBG by an androgenic mechanism, but it raises testosterone production directly, possibly through ovarian hyperandrogenism and PCOS-like effects. A Finnish cohort study (Isojarvi et al., Lancet 1993) found a high prevalence of polycystic ovaries and hyperandrogenism in women starting valproate before age 20. The result is high total testosterone with relatively normal SHBG, so free testosterone is disproportionately elevated. Awareness of this pattern matters for any woman of reproductive age on valproate.

SHBG Across Women's Life Stages

Reproductive Years

In regularly cycling women, SHBG fluctuates modestly across the menstrual cycle, peaking near ovulation in response to the estradiol surge. This variation is small compared to drug effects but means a mid-cycle draw and a late luteal draw can differ by 15 to 20 percent. Standardizing the draw to the early follicular phase (days 2 to 5) reduces this variability.

PCOS

Low SHBG is a hallmark of PCOS. The Androgen Excess and PCOS Society guidelines recognize that in PCOS, SHBG suppression by insulin creates a vicious cycle: low SHBG raises free androgen, which worsens insulin resistance, which further suppresses SHBG. For this population, a total testosterone in the upper-normal range paired with very low SHBG often yields a free testosterone clearly above the female reference range. Reporting only total testosterone misses the clinical picture entirely.

Metformin raises SHBG in women with PCOS by improving insulin sensitivity. A meta-analysis in the Journal of Clinical Endocrinology and Metabolism (Tang et al., 2012) confirmed that metformin significantly increased SHBG alongside reductions in free androgen index. This is a drug-on-SHBG interaction that works in your favor clinically, but it still means your labs will shift substantially depending on whether you are tested before or after starting metformin.

Trying to Conceive and Fertility Treatment

SHBG is not a routine fertility marker, but it appears on extended androgen panels ordered in fertility workups. Gonadotropin stimulation for IVF raises estradiol to supraphysiologic levels, driving SHBG sharply upward during the stimulation cycle. Interpreting any free hormone level drawn during an IVF cycle requires knowing exactly what phase of stimulation the blood was taken in.

Pregnancy

SHBG rises dramatically in pregnancy, driven by placental and hepatic estrogen production. By the third trimester, SHBG levels are 5 to 10 times the non-pregnant baseline. This extraordinary rise effectively sequesters androgens, protecting the female fetus from maternal testosterone virilization. No drug adjustment to SHBG interpretation is needed in pregnancy; the elevation is expected and physiological.

Perimenopause

In the menopause transition, estradiol production becomes erratic. SHBG follows these fluctuations. A woman in early perimenopause with still-adequate estradiol may have normal SHBG. By late perimenopause, when estradiol falls persistently, SHBG drops with it, and free testosterone may paradoxically rise even as total testosterone also falls. This pattern can produce androgen-mediated symptoms (facial hair, scalp hair thinning) at a life stage when women may not expect them.

Post-Menopause and Hormone Therapy Route

The route of estrogen administration in hormone therapy (HT) determines the SHBG effect completely.

Oral estradiol or conjugated equine estrogens increase hepatic SHBG production through first-pass metabolism. Transdermal estradiol (patch, gel, spray) bypasses the liver and does not raise SHBG at standard doses. A randomized trial by Vongpatanasin et al. (2003, Hypertension) confirmed that transdermal and oral estradiol produce equivalent systemic estradiol concentrations but divergent SHBG levels. This means a post-menopausal woman switching from oral to transdermal HT may see her SHBG fall and her free testosterone rise, resolving low-libido symptoms without changing her testosterone prescription at all.

The WomanRx Route-SHBG-Free Androgen Framework: When a post-menopausal woman on HT reports low libido despite "normal" testosterone levels, check which route her estrogen uses. If oral, her SHBG may be artificially elevated by 60 to 150 percent. Switching to transdermal estrogen alone, before adding testosterone, may raise free testosterone into an adequate range without any androgen prescription.

Pregnancy, Lactation, and Drug Safety: What to Know

This section applies to women in reproductive years and those using medications that interact with SHBG during pregnancy or while breastfeeding.

Pregnancy Safety by Drug Class

Oral contraceptives are stopped before confirmed pregnancy and are not used during pregnancy. Any unintended pregnancy while on a COC warrants prompt obstetric consultation; COC exposure in early pregnancy has not been shown to cause major structural fetal malformations, but no hormone-based contraceptive is intended for pregnancy continuation.

Levothyroxine is safe in pregnancy and the dose requirement increases by approximately 25 to 50 percent from the first trimester onward. ACOG recommends TSH monitoring every 4 weeks during the first half of pregnancy in women with hypothyroidism. SHBG will be physiologically elevated in pregnancy regardless of levothyroxine dose.

Metformin is used off-label in pregnancy for PCOS-related miscarriage prevention and gestational diabetes management. The Endocrine Society Clinical Practice Guideline for PCOS notes that metformin is not approved by the FDA for use in pregnancy but has a substantial safety record. It crosses the placenta and is present in breast milk at low concentrations.

Anticonvulsants present a more complex picture. Carbamazepine and phenytoin are associated with neural tube defects and require reliable contraception and pre-conception folic acid supplementation. Valproate carries the highest teratogenic risk of any anticonvulsant, including a 1 to 2 percent risk of neural tube defects and neurodevelopmental consequences. The FDA issued a safety communication requiring a Pregnancy Exposure Registry for valproate. Women of reproductive age on valproate must use reliable contraception unless the epilepsy is otherwise uncontrolled.

Androgens (testosterone, DHEA, danazol) are contraindicated in pregnancy. Exogenous androgens virilize a female fetus. Women using testosterone for HSDD or performance should use reliable non-hormonal or progestin-only contraception, as combined oral contraceptives are counterproductive given their SHBG-raising and free-testosterone-suppressing effects.

Tamoxifen is contraindicated in pregnancy and requires effective contraception during treatment and for at least 9 months after the final dose per current prescribing guidance.

Lactation

SHBG itself does not transfer in clinically meaningful amounts in breast milk. The concern during lactation is the drugs that alter SHBG. Oral estrogen-containing contraceptives are generally avoided while breastfeeding because estrogen may suppress milk supply, particularly in the first 6 weeks postpartum. ACOG Practice Bulletin 206 recommends progestin-only methods for lactating women who need hormonal contraception.

Who Should Get an SHBG (Extended) Panel

SHBG (extended) is most useful when total testosterone alone does not explain symptoms.

Strong indications:

• PCOS evaluation where total testosterone is borderline but androgen symptoms are prominent
• Post-menopausal women on oral HT with unexplained low libido or fatigue
• Women starting or stopping oral contraceptives with persistent sexual side effects
• Any woman on enzyme-inducing anticonvulsants where androgen deficiency is suspected
• Fertility workup requiring full androgen characterization
• Women on metformin for PCOS wanting to track treatment response

Situations where SHBG (extended) adds limited value:

• Active pregnancy (SHBG is always physiologically elevated; free hormone calculations are unreliable)
• Women mid-cycle on COCs without plans to change methods (results reflect pill pharmacology, not baseline)
• Screening in otherwise asymptomatic women without hormonal complaint

How to Improve the Accuracy of Your SHBG Draw

These steps reduce pre-analytical noise and medication confounding.

1. Draw in the early follicular phase (days 2 to 5 of your cycle) if you are premenopausal and off hormonal contraception.
2. Fast for at least 8 hours before the draw. Acute insulin secretion after a meal transiently suppresses SHBG.
3. Tell your provider about every supplement, including DHEA, androstenedione, protein powders with added hormones, and herbal androgens such as tribulus or ashwagandha. These are not always captured on medication lists but do affect SHBG.
4. If your clinical question is baseline SHBG unaffected by oral contraceptives, discuss timing the draw at least 3 months after stopping the pill.
5. Document the exact time of your last dose of thyroid hormone before the draw. Taking levothyroxine immediately before blood draw can produce transient free T4 spikes that do not reflect steady-state levels, though the SHBG effect is driven by steady-state thyroid status.

The Endocrine Society position statement on testosterone measurement in women recommends that labs measuring free testosterone by equilibrium dialysis (the gold standard direct measurement, not calculation) report the analytical method used, because calculated free testosterone from immunoassay-based total T carries a coefficient of variation of 15 to 30 percent in women.

Frequently Asked Questions